Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
3 other identifiers
observational
1,000
7 countries
14
Brief Summary
1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2025
14 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 4, 2025
CompletedFirst Posted
Study publicly available on registry
April 11, 2025
CompletedStudy Start
First participant enrolled
May 12, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 1, 2026
March 27, 2026
March 1, 2026
1.5 years
April 4, 2025
March 25, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
AMD Classification by Participant Count
A meticulously curated and diverse Benchmark dataset, featuring reference standard level 1 classification and annotated images for a wide range of AMD phenotypes is the primary outcome. Diversity of the dataset will in part be measured by classifying AMD status. The goal is to have: * 20% participants with no AMD * 30% participants with Early AMD * 30% participants with Intermediate AMD * 10% participants with Geographic Atrophy (GA) * 10% participants with Neovascular age-related macular degeneration (nAMD)
up to 18 months
Geographic Location by Participant Count
A meticulously curated and diverse Benchmark dataset, featuring reference standard level 1 classification and annotated images for a wide range of AMD phenotypes is the primary outcome. Diversity of the dataset will in part be measured by geographic location. 1000 participants from up to 25 global sites will be included.
up to 18 months
Study Arms (1)
AMD Benchmark Imaging Dataset Cohort
Study Procedures Include: * Patient history: demographics (age, sex, ethnicity, race), smoking history, family history of AMD * Physical exam: height and weight * Snellen best-corrected visual acuity (BCVA) * AMD classification (Beckman scale)
Interventions
Eligible participants will undergo one retinal imaging session of both eyes for the following: * Single field stereo color fundus photography (cFP) - pre and post dilation * Macular spectral domain-optical coherence tomography (SD-OCT)
Eligibility Criteria
Approximately 1000 participants from up to 25 sites in the United States, Europe, Asia, South America, Africa, and Australia will be enrolled and balanced by age, sex, and AMD level (worse eye selected as study eye). Every region listed above may not be represented and additional regions/countries not listed above may be included.
You may qualify if:
- Participants greater than or equal to 50 years of age at time of signing Informed Consent Form
- Willing to comply with all study procedures and sign the Informed Consent Form (ICF)
- Individuals with normal healthy eyes or diagnosed with any stage of Age-Related Macular Degeneration (treatment naïve patients with early, intermediate, or late AMD). The diagnosis and eligibility review will be confirmed by Central Reading Center.
You may not qualify if:
- Therapeutic treatment for any type of AMD, in either eye. Supplements, such as AREDS2 formula, are allowed.
- Unable to acquire adequate quality images, as evaluated by the Central Reading Center
- Severe vision loss requiring urgent surgery
- Contraindicated for acquiring retinal images due to narrow anterior chamber angles or hypersensitivity to light
- A systemic or ocular condition that in the opinion of the Investigator would preclude participation in the study
- Unwilling to sign informed consent form
- Currently or previously enrolled in an interventional AMD clinical trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (14)
Bergstrom Eye Research LLC
Fargo, North Dakota, 58103, United States
Erie Retina Research
Erie, Pennsylvania, 16507, United States
Retina Foundation of the Southwest
Dallas, Texas, 75231, United States
Valley Retina Institute
McAllen, Texas, 78503, United States
Retina Consultants of Texas (Houston)
The Woodlands, Texas, 77384, United States
University of Utah - John A. Moran Eye Center
Salt Lake City, Utah, 84132, United States
University Station Eye Care Clinic
Madison, Wisconsin, 53705, United States
Charles Research Center
Buenos Aires, Argentina
Adelaide Eye and Retina Centre
Adelaide, 5000, Australia
Centre Hospialier Intercommunal de Paradis (Centre Monticelli Paradis)
Marseille, 13008, France
University of Bonn - Department of Ophthalmology
Bonn, 53127, Germany
Sankara Nethralaya, Medical Research Foundation
Chennai, Tamil Nadu, 600006, India
Aravind Eye Hospital
Chennai, Tamil Nadu, 641014, India
Aga Khan University
Karachi, 74800, Pakistan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Amitha Domalpally, MD, PhD
UW School of Medicine and Public Health
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 4, 2025
First Posted
April 11, 2025
Study Start
May 12, 2025
Primary Completion (Estimated)
November 1, 2026
Study Completion (Estimated)
November 1, 2026
Last Updated
March 27, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share